ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7,240
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable
ResMed (NYSE:RMD) Frequently Asked Questions
What is ResMed's stock symbol?
ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
How often does ResMed pay dividends? What is the dividend yield for ResMed?
ResMed declared a quarterly dividend on Friday, January 31st. Shareholders of record on Thursday, February 13th will be given a dividend of $0.39 per share on Thursday, March 19th. This represents a $1.56 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Wednesday, February 12th. View ResMed's Dividend History.
How were ResMed's earnings last quarter?
ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Thursday, January, 30th. The medical equipment provider reported $1.21 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.01 by $0.20. The medical equipment provider had revenue of $736.20 million for the quarter, compared to analyst estimates of $723.08 million. The firm's revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.00 EPS. View ResMed's Earnings History.
When is ResMed's next earnings date?
What price target have analysts set for RMD?
8 brokerages have issued 1 year price objectives for ResMed's shares. Their forecasts range from $95.00 to $174.00. On average, they expect ResMed's stock price to reach $134.50 in the next year. This suggests that the stock has a possible downside of 23.8%. View Analyst Price Targets for ResMed.
What is the consensus analysts' recommendation for ResMed?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed.
Has ResMed been receiving favorable news coverage?
Media headlines about RMD stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ResMed earned a news impact score of 2.0 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for ResMed.
Who are some of ResMed's key competitors?
Some companies that are related to ResMed include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).
What other stocks do shareholders of ResMed own?
Who are ResMed's key executives?
ResMed's management team includes the folowing people:
- Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
- Mr. Robert A. Douglas, Pres & COO (Age 59)
- Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
- Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
- Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)
Who are ResMed's major shareholders?
ResMed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (5.39%), State Street Corp (4.45%), FMR LLC (4.15%), Baillie Gifford & Co. (3.15%), Bank of New York Mellon Corp (0.86%) and Sumitomo Mitsui Trust Holdings Inc. (0.54%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.
Which institutional investors are selling ResMed stock?
RMD stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Westpac Banking Corp, Schroder Investment Management Group, AQR Capital Management LLC, FMR LLC, Skandinaviska Enskilda Banken AB publ , Bank of America Corp DE and Amundi Pioneer Asset Management Inc.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.
Which institutional investors are buying ResMed stock?
RMD stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, WCM Investment Management LLC, Renaissance Technologies LLC, Credit Suisse AG, Franklin Resources Inc., Victory Capital Management Inc., Kornitzer Capital Management Inc. KS and Assenagon Asset Management S.A.. View Insider Buying and Selling for ResMed.
How do I buy shares of ResMed?
Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ResMed's stock price today?
One share of RMD stock can currently be purchased for approximately $176.60.
MarketBeat Community Rating for ResMed (NYSE RMD)
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
